GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
I

Invex Therapeutics IXC.AX · AUD

Health Care · ASX · 🇦🇺 Australia

Compare

0.09

-10.00%

Close of 3 Nov 2026, in AUD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in AUD, from our data supplier.

FY2024

Revenue

A$1.7m

FY2018FY2024

Net income

−A$1.6m

FY2018FY2024

Free cash flow

−A$2.4m

FY2018FY2024

Shareholders' equity

A$5.7m

FY2018FY2024

Income statement

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
RevenueA$1.7mA$1.3mA$262,100A$158,800A$165,700A$100—
Research and developmentA$2.0mA$7.4mA$3.0mA$1.1mA$1.6mA$59,900—
Operating income−A$1.6m−A$7.7m−A$4.0m−A$2.3m−A$3.1m−A$127,000−A$10,000
Net income−A$1.6m−A$7.7m−A$4.0m−A$2.3m−A$3.4m−A$232,100−A$10,000
Diluted earnings per share-0.02-0.10-0.05-0.03-0.06-0.00—

Balance sheet

At each fiscal year end

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Total assetsA$6.1mA$22.8mA$29.5mA$32.7mA$26.4mA$12.4mA$640,000
Cash and short-term investmentsA$6.0mA$22.5mA$29.3mA$32.7mA$26.3mA$12.2mA$500,000
Total liabilitiesA$431,600A$1.6mA$1.0mA$658,600A$2.0mA$935,500A$40,000
Shareholders' equityA$5.7mA$21.2mA$28.5mA$32.1mA$24.4mA$11.4mA$600,000
Shares outstanding75m75m75m75m56m55m55m

Cash flow

Fiscal years

FY2024FY2023FY2022FY2021FY2020FY2019FY2018
Cash from operations−A$2.4m−A$6.9m−A$3.4m−A$1.7m−A$1.6m−A$230,100—
Capital spending—————−A$8,200—
Free cash flow−A$2.4m−A$6.9m−A$3.4m−A$1.7m−A$1.6m−A$238,300—

Latest quarters

By quarter end

Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022Dec 2021
RevenueA$345,900A$115,700A$1.3mA$376,600A$461,300A$794,900A$39,600A$222,600
Operating income−A$120,300−A$356,500A$470,900−A$2.1m−A$3.9m−A$3.8m−A$2.2m−A$1.8m
Net income−A$120,300−A$356,500A$470,900−A$2.1m−A$3.9m−A$3.8m−A$2.2m−A$1.8m
Diluted earnings per share-0.00-0.000.01-0.03-0.05-0.05-0.03-0.02
Total assetsA$5.5mA$5.9mA$6.1mA$6.3mA$22.8mA$25.9mA$29.5mA$31.5m
Cash and short-term investmentsA$5.4mA$5.8mA$6.0mA$6.2mA$22.5mA$25.4mA$29.3mA$31.4m
Shareholders' equityA$5.2mA$5.4mA$5.7mA$5.3mA$21.2mA$24.7mA$28.5mA$30.5m

Growth per year

Compound annual rate

3 years5 years10 years
Revenue20.8%22.7%—
Operating income-50.6%-31.2%—
Net income-50.6%-32.3%—

Average margins

Over each period

1 year3 years5 years10 years
Operating margin-97.8%-375.2%-478.7%—
Net margin-97.8%-375.2%-485.6%—

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020
Price to earnings-18.9-3.0-0.8-1.5-3.4-1.7
Price to sales19.52.94.822.748.435.1

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 8 Dec 2023.

FY2024
Paid in the year0.002

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.